Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ImmunoPrecise Antibodies Ltd. - Common Stock (NQ: IPA )

0.4001 -0.0200 (-4.76%)
Streaming Delayed Price Updated: 3:56 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 192,811
Open 0.4175
Bid (Size) 0.4000 (5)
Ask (Size) 0.4098 (10)
Prev. Close 0.4201
Today's Range 0.3988 - 0.4400
52wk Range 0.3248 - 2.600
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
IPA to Present at The Microcap Conference 2025
Via ACCESSWIRE
IPA to Present at The Microcap Conference 2025
From ImmunoPrecise Antibodies Ltd.
Via Business Wire

Performance

YTD
-76.46%
-76.46%
1 Month
+14.84%
+14.84%
3 Month
-37.73%
-37.73%
6 Month
-59.61%
-59.61%
1 Year
-70.36%
-70.36%

More News

Read More
ImmunoPrecise Antibodies: Q2 Earnings Insights
Via Benzinga
ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
A Preview Of ImmunoPrecise Antibodies's Earnings
Via Benzinga
Earnings Scheduled For December 10, 2024
Via Benzinga
IPA to Present at The Benchmark Company’s Upcoming Discovery One-on-One Investor Conference
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
IPA to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025 on December 10, 2024
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
“Emerging Innovators Transforming Global Markets: IPA, CRDL, KXIN, GNS, PRSO in Sectors”
Via AB Newswire
Topics Electric Vehicles
Exposures Electric Vehicles Product Safety
$20 Billion Market Breakthrough: IPA Pioneers High-Impact Antibody Development for Next-Generation ADC Cancer Therapies
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise to Host TECHDAY: Cutting-Edge AI and Biologics Innovation
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise Advances Anti-Aging Research with Mayo Clinic Study, Poised to Tap into $81 Billion Market with AI Technology
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise Antibodies to Participate at the AI Driven Drug Discovery Summit USA 2024
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise Antibodies Celebrates Nobel Prize in Chemistry, Advances in AI-Powered Protein Design
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise Subsidiary Signs Material Transfer Agreement with Biotheus
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise Antibodies Advances Therapeutic Innovation with Groundbreaking Rabbit Antibody Developments
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025 on September 16, 2024
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise Antibodies Receives Nasdaq Notification Regarding Minimum Bid Requirements
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise Antibodies (IPA) Reports Financial Results and Business Updates for Fourth Quarter and Full Fiscal Year 2024
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise Antibodies to Reschedule Financial Results and Recent Business Highlights Report for Fourth Quarter and Fiscal Year-End 2024
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise Announces Financing Agreement with Yorkville Advisors Global, LP of up to $3.0 Million Aggregate Principal Amount of Convertible Debentures
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Fiscal Year End 2024 on July 25th, 2024
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise Appoints Kristin Taylor as Chief Financial Officer
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.